WEKO3
アイテム
Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities
http://hdl.handle.net/2237/26117
http://hdl.handle.net/2237/26117e0f80cc0-e8e6-4c3c-ba66-c8b0459a6e3c
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
|
![]() |
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-04-21 | |||||
タイトル | ||||||
タイトル | Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities | |||||
言語 | en | |||||
著者 |
Kuramitsu, Shunichiro
× Kuramitsu, Shunichiro× Yamamichi, Akane× Ohka, Fumiharu× Motomura, Kazuya× Hara, Masahito× Natsume, Atsushi |
|||||
アクセス権 | ||||||
アクセス権 | open access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
抄録 | ||||||
内容記述 | Patients with glioblastoma have a very poor prognosis. Adoptive cellular therapy (ACT) is defined as the collection of circulating or tumor-infiltrating lymphocytes, their selection, modification, expansion and activation, and their re-administration to patients in order to induce antitumor activity. Although various ACTs have been attempted, most failed to improve the outcome. Immune checkpoint blockade antibodies and T cell engineering with tumor-specific chimeric antigen receptors suggest the emergence of a new era of immunotherapy. Here, we summarize approaches with ACTs using genetically modified T cells, which have been improved by enhancing their antitumor activity, and discuss strategies to develop these therapies. The mechanisms by which gliomas modulate and evade the immune system are also discussed. | |||||
言語 | en | |||||
内容記述タイプ | Abstract | |||||
出版者 | ||||||
言語 | en | |||||
出版者 | Future Medicine | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプresource | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | journal article | |||||
出版タイプ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.2217/imt-2016-0076 | |||||
ISSN | ||||||
収録物識別子タイプ | PISSN | |||||
収録物識別子 | 1750-743X | |||||
書誌情報 |
en : Immunotherapy 巻 8, 号 12, p. 1393-1404, 発行日 2016-12 |
|||||
著者版フラグ | ||||||
値 | author | |||||
URI | ||||||
識別子 | http://doi.org/10.2217/imt-2016-0076 | |||||
識別子タイプ | DOI | |||||
URI | ||||||
識別子 | http://hdl.handle.net/2237/26117 | |||||
識別子タイプ | HDL |